Published in Women's Health Weekly, July 10th, 2008
The therapeutic breast cancer vaccine AE37 uses a peptide antigen (immune-stimulating fragment) of a cancer gene known as HER-2/neu. This gene/protein is present in many types of cells, but it is over-expressed in a high proportion of breast cancers as well as many others. The vaccine is being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex.
Dr. George Peoples of the Brooke Army Medical Center, who presented...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly